FEB 27, 2019 10:30 AM PST

The Current State-of-the-Art Tissue Expression Analysis Platform for Detection & Quantification of Target & Biomarker mRNAs, Splice Variants and Mutations in Preclinical & Clinical Tissues

SPONSORED BY: Advanced Cell Diagnostics
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Vice President of Business Development, Advanced Cell Diagnostics
    Biography
      Dr. Christopher Bunker is the Vice President of Business Development at Advanced Cell Diagnostics (ACD) in Newark, California. Dr. Bunker completed his doctoral research in Biological Chemistry at Harvard University and a Leukemia Society of America postdoctoral fellowship in molecular genetics at UCSF. He was a senior scientist in cancer functional genomics at Genome Therapeutics before joining Cell Signaling Technology at its inception in 2000. Dr. Bunker received an M.B.A from Boston University. He joined ACD in 2010, where he has led its assay services business for the past 8 years.

    Abstract:

    Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and safety studies and in biomarker development.  RNAscope is clinically validated and performs reliably on routine FFPE archival human tissues and clinical biopsies and any animal model tissues.  Detection limits are at single molecule level, enabling quantitative, cell-specific expression analysis within tissue microenvironments.  There are over 15,000 RNAscope probes in use and over 1,800 publications – more than 2-per-day.  Continuing advances in ACD RNA ISH technology are enable a wide range of applications, including:

    -    Multiplexed RNA ISH
    -    Dual ISH/IHC for target analysis combined with cell marker staining
    -    Isoform-specific assays with exon junction probes
    -    Tissue-based gene edit detection
    -    Viral RNA and DNA genome detection
    -    AAV gene therapy biodistribution analysis
    -    CAR-TCR T cell detection and tumor infiltration assays with lentiviral probes

    RNAscope technologies are enabling faster and more rigorous tissue-based target and biomarker research with cell-specific, single-molecule sensitive RNA detection in the context of complex disease microenvironments.  The technology, methods and its applications will be illustrated.

    Learning Objectives:

    1. How RNAscope® in situ hybridization is utilized for tissue-based, cell-specific expression analysis
    2. How RNAscope® is enabling gene therapy and cell therapy tissue biodistribution analysis


    Show Resources
    You May Also Like
    FEB 26, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 26, 2019 09:00 AM PST
    DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
    NOV 15, 2018 10:00 AM PST
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    FEB 27, 2019 08:00 AM PST
    C.E. CREDITS
    FEB 27, 2019 08:00 AM PST
    DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
    FEB 20, 2019 09:00 AM PST
    C.E. CREDITS
    FEB 20, 2019 09:00 AM PST
    DATE:  February 20, 2019TIME:  9:00am PST  ...
    MAR 26, 2019 02:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    MAR 20, 2019 09:00 AM PDT
    C.E. CREDITS
    MAR 20, 2019 09:00 AM PDT
    DATE:  March 20, 2019TIME:  9:00am PDT...
    Loading Comments...
    Show Resources